<DOC>
	<DOCNO>NCT00238797</DOCNO>
	<brief_summary>The purpose study determine efficacy gefitinib ( IressaTM ) combination radiotherapy patient glioblastoma multiforme .</brief_summary>
	<brief_title>A Phase II Exploratory , Multicentre , Open-label , Non-comparative Study ZD1839 ( Iressa ) Radiotherapy Treatment Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed informed consent histologicallyor cytologicallyconfirmed glioblastoma multiforme age 18 year old Have prior radiation therapy , immunotherapy , gene therapy and/or chemotherapy glioblastoma coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ know severe hypersensitivity ZD1839 excipients product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Brain tumour</keyword>
</DOC>